(Published with Decision No. 3003/QðBYT dated 19/8/2009 of the Minister of Health)
Skin and mucosal conditions are extremely common in all children and adults in particular in HIV-infected adults and children and are one of the commonest daily management problems faced by health care workers caring for patients with HIV infection
Occasional anxiety is a normal part
of life. You might worry about things
like health, money, or family
problems. But people with
generalized anxiety disorder (GAD)
feel extremely worried or feel
nervous about these and other
things—even when there is little or
no reason to worry about the...m.
People with GAD find it difficult to
control their anxiety and stay
focused on daily tasks.
The good news is that GAD is
treatable. Call your doctor to talk
about your symptoms so that you
can feel better.
more
Research Article
BMC Infectious Diseases 2014, 14:91/1471-2334/14/91
Depression Research and Treatment
Volume 2012, Article ID 962860, 8 pages
doi:10.1155/2012/962860
Asthma is the most common noncommunicable disease in children, and among the most common in adults. According to the most recent estimates from the Global Asthma Network Phase I study, around one in 10 children and adults have symptoms of asthma and one in 20 school-aged children have severe asthma ...symptoms, with marked variations in prevalence and in prevalence trends between countries and regions of the world. The Global Burden of Disease Study estimated that asthma caused the loss of 21.6 million healthy years of life (disability-adjusted life years) and 461 069 deaths in 2019. Approximately 90% of the asthma burden of disease is borne by people living low and middle income countries (LMICs). Some countries report very high (up to 90%) rates of uncontrolled asthma. While the prevalence of asthma is highest in countries with a high Socio-Demographic Index (SDI), death rates from asthma are highest in countries with low and lower middle incomes.
more
This report’s central premise is that diagnostics and therapeutics, and associated test to treat strategies, are fundamental components of the pandemic response, both for COVID-19 and for future health threats. Two years into the COVID-19 pandemic, this report reflects on the main challenges and k...ey solutions on the road to equitable access to diagnostics and therapeutics.
This report draws from experience gained through the Access to COVID-19 Tools (ACT) Accelerator Diagnostics and Therapeutics pillars, and includes the perspectives of collaborating stakeholders (countries, civil society representatives and the private sector). Building on these findings, this report proposes sixteen recommended actions to address what have been identified as key structural challenges and specifies a potential owner for each action.
more
An Act to provide for the efficient and comprehensive regulation and control of food, drugs, medical devices, cosmetics, herbal drugs and poisons and to repeal the Food
(Control of Quality) Act, 1978, the Pharmaceuticals and Poisons Act, 1978 and to provide for related matters.
nterim guidance, first issued 25 January 2021, updated 15 June 2021, updated 19 November 2021, updated 23 February 2022, updated 18 August 2022
Responses to epidemics, emergencies and disasters raise many ethical issues for the people involved, including public health specialists and policy makers. This training manual provides material on ethical issues in research, surveillance and patient care in these difficult contexts.
SCOPING QUESTION: In the management of prescription opioid dependence, does supervised dosing with a long-acting opioid medication result in less opioid use and related harms than non-prescription, detoxification or usual care?
The reports bring together the latest findings and conclusions about the state of resistance to artemisinins and artemisinin-based combination therapy (ACT), summarize WHO’s current policy and treatment recommendations, and highlight areas of concern.
Drug registration in Kenya started in 1982; the process mainly involves an evaluation committee at the Kenya Pharmacy and Poisons Board (PPB) that aims to approve products based on quality, safety and efficacy.
first issued 18 August 2022